About: Baricitinib restrains the immune dysregulation in COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Baricitinib restrains the immune dysregulation in COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Baricitinib restrains the immune dysregulation in COVID-19 patients
Creator	Comel, Andrea Fiore, Alessandra Lunardi, Claudio Tinazzi, Elisa Barouni, Roza Batani, Veronica Bazzoni, Paolo Bronte, Bronte, Vincenzo Caligola, Simone Canè, Stefania De Sanctis, Francesco Donadello, Katia Facciotti, Federica Friso, Simonetta Hofer, Francesca Iezzi, Manuela Mosaner, Walter Musiu, Chiara Olivieri, Oliviero Pelicci, Piergiuseppe Petrova, Varvara Pinton, Laura Pizzolo, Francesca Polati, Enrico Rampudda, Mariaelisa Righetti, Daniela Torroni, Lorena Trovato, Rosalinda Ugel, Stefano Vella, Antonio
Source	MedRxiv
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing pandemic coronavirus disease 2019 (COVID-19). The majority of patients with COVID-19 have a good prognosis, but variable percentages in different countries develop pneumonia associated with lymphocytopenia and severe inflammatory response due to uncontrolled release of cytokines. These immune mediators are transcriptionally regulated by JAK-STAT molecular pathways, which can be disabled by small molecules. Here, we provide evidences on the efficacy of baricitinib, a JAK1/JAK2 inhibitor, in correcting the immune abnormalities observed in patients hospitalized with COVID-19. Indeed, we demonstrate a significant reduction in serum levels of interleukin (IL)-6, IL-1{beta} and tumor necrosis factor (TNF), a rapid recovery in circulating T and B cell frequencies and an increased antibody production against SARS-CoV-2 spike protein in baricitinib-treated patients. Moreover, treated patients underwent a rapid reduction in oxygen flow need and progressive increase in the P/F. Our work provides the basis on developing effective treatments against COVID-19 pathogenesis using on-target therapy.
has issue date	2020-06-29(xsd:dateTime)
bibo:doi	10.1101/2020.06.26.20135319
has license	medrxiv
sha1sum (hex)	7d9c9fcc31c0df1a04af286a6dae7854b8eaafc0
schema:url	https://doi.org/10.1101/2020.06.26.20135319
resource representing a document's title	Baricitinib restrains the immune dysregulation in COVID-19 patients
resource representing a document's body	covid:7d9c9fcc31c0df1a04af286a6dae7854b8eaafc0#body_text
is schema:about of	named entity 'antibody' named entity 'efficacy' named entity 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'protein' named entity 'Here' named entity 'pathogenesis' named entity 'DISABLED' named entity 'PANDEMIC' named entity 'COUNTRIES' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'INCREASED ANTIBODY PRODUCTION' named entity 'LEVELS' named entity 'DEVELOPING' named entity 'THERAPY' named entity 'effective' named entity 'evidences' named entity 'causative' named entity 'patients' named entity 'JAK-STAT' named entity 'severe' named entity 'observed' named entity 'therapy' named entity 'abnormalities' named entity 'pandemic' named entity 'levels' named entity 'good' named entity 'inflammatory response' named entity 'COVID' named entity 'serum levels' named entity 'baricitinib' named entity 'antibody' named entity 'TNF' named entity 'baricitinib' named entity 'JAK1' named entity 'immune dysregulation' named entity 'prognosis' named entity 'pharmacodynamics' named entity 'monocytes' named entity 'cytokine' named entity 'SARS-CoV-2' named entity 'phenotype' named entity 'IL-8' named entity 'D-dimer' named entity 'baricitinib' named entity 'preprint' named entity 'neutrophils' named entity 'plasma' named entity 'lower respiratory tract' named entity 't-distributed stochastic neighbor embedding' named entity 'lung' named entity 'X-ray analysis' named entity 'cell proliferation' named entity 'baricitinib' named entity 'prognostic factor' named entity 'baricitinib'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software